BackAgeX Therapeutics Overview

AgeX Therapeutics Other Current Liabilities

Track AgeX Therapeutics's other current liabilities ($3.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$3.51M
14737.50% YoYΔ $3.54M vs prior year quarter

Peer average

Loading

AgeX Therapeutics Other Current Liabilities History

Loading

AgeX Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

AgeX Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AgeX Therapeutics (AGE) FAQ

AgeX Therapeutics (AGE) currently reports a other current liabilities of $3.5M as of March 2026. That compares with $-24K in the prior-year period — up 14737.5% year over year. Use the charts on this page to explore AgeX Therapeutics's other current liabilities history and peer comparisons.

AgeX Therapeutics's other current liabilities increased from $-24K to $3.5M — a 14737.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AgeX Therapeutics reported $3.5M in other current liabilities as of March 2026. That compares with $-24K in the prior-year period — up 14737.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $3.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AgeX Therapeutics, and consider following AGE for alerts when major investors trade the stock.

AgeX Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $3.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGE with unrelated industries.